- State-of-the-art site will enable rapid delivery of engineered cell lines
- Powering ready-to-use edited cell-line portfolio expansion
- Enable comprehensive customization for research, diagnostic and therapeutic development
PR Newswire
CAMBRIDGE, England, Dec. 8, 2020